Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676788 | 1.00 | HSD17B1 (0.36) | HSD17B1HSD17B2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL1676482 | 0.94 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL1676484 | 0.94 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL1676523 | 0.90 | RAB9A (0.37) | HSD17B1HSD17B2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL1676527 | 0.90 | RAB9A (0.37) | HSD17B1HSD17B2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL1676260 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL1676258 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL1676085 | 0.88 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL1676083 | 0.88 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL1676140 | 0.84 | KDM4E (0.42) | SMN1; SMN2KDM4ENPC1CRHBPRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | claimed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | HSD17B1 228/4885HSD17B2 319/4885SMN1; SMN2 4417/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | HSD17B1 228/4885HSD17B2 319/4885SMN1; SMN2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.